Jetrea (ocriplasmin) / Oxurion - LARVOL DELTA

Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System. (PubMed, Eye (Lond)) - "This study provides a stratified list of medications with disproportionate reporting signals for RD. Further high-quality epidemiological and mechanistic studies are warranted to validate the potential causality associations between these medications and RD. Assessment of drug-related retinal detachment using real-world large-scale data."

Adverse events • Journal • Real-world evidence • Erectile Dysfunction • Oncology • Ophthalmology • Retinal Disorders

Risk factors and efficacy of different intravitreal treatment options for symptomatic focal vitreomacular traction with or without full-thickness macular hole. (PubMed, Int Ophthalmol) - "Both PVL and IVO showed similar VMT resolution rates. PVL was less effective in closing FTMH and had higher side effects compared to IVO. In the presence of retinal pathologies, PVL is preferable to IVO."

Journal • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders

Differential Item Functioning With the National Eye Institute Visual Function Questionnaire-25 in Patients With Vitreomacular Traction (ISPOR 2025) - "This PROM was administered in Phase 3 ocriplasmin randomized clinical trials to evaluate changes in vision-related function in patients with vitreomacular traction (VMT) with or without epiretinal membrane (ERM) or macular hole (MH)... Notable DIF was not observed with VFQ-VFS or VFQ-SES items. Minimal DIF or item bias (interactions between individual items and types of respondents defined by sample characteristics) were observed with 3 VFQ-SES items and 2 VFQ-VFS items."

Clinical • Ophthalmology • Retinal Disorders

Is the National Eye Institute Visual Function Questionnaire-25 suitable for measuring vision-related quality of life in patients with Vitreomacular Traction? (ARVO 2025) - "Purpose Metamorphopsia and other symptoms of vitreomacular traction (VMT) are not quantifiable on ETDRS charts, so a patient-reported outcome (PRO) measure was used in the Phase 3 ocriplasmin clinical trials to evaluate changes in vision-related function...Our key finding is that many questions in the NEI VFQ-25 are not very relevant for people experiencing symptoms caused by vitreomacular traction. This suggests the questionnaire may not fully capture the specific challenges faced by these patients."

Clinical • HEOR • Ophthalmology • Retinal Disorders

A Causal Inference Approach to Mediation Analysis in Vitreomacular Traction: How Much Does Traction Resolution Mediate Functional Outcomes? (PubMed, J Mark Access Health Policy) - "The direct effects are 8.3%, 12.1%, and 24.1% respectively, capturing the effect of treatment on the probability of a vision improvement if ocriplasmin left each participant's VMAR status unchanged. The relative treatment effect of ocriplasmin on the functional outcome VA-I is to a large extent the result of its effect on VMAR, while an improvement in the patient-reported outcomes VFQ-I or VF-I was only partially mediated by VMAR."

Journal

OPTICAL COHERENCE TOMOGRAPHY FEATURES ASSOCIATED WITH VITREOMACULAR TRACTION RELEASE AND MACULAR HOLE SIZE PROGRESSION FOLLOWING TREATMENT WITH OCRIPLASMIN. (PubMed, Retina) - "In patients with VMT-associated MHs, the risk of MH enlargement following ocriplasmin is negatively correlated with the nasal PVC angle size and is increased if the ratio of the temporal to nasal angle is >1."

Journal • Retrospective data • Retinal Disorders

Current treatment strategies for vitreomacular traction and macular holes: a survey of retinal specialists in Germany (PubMed, Ophthalmologie) - "The results presented provide an overview of the consensus and controversies in the current treatment options for VMT and MF. With the help of a homogeneous and experienced group of retinal experts, it was possible to develop individual treatment strategies."

Journal • Retinal Disorders

Macrocyclic inhibitors targeting the prime site of the fibrinolytic serine protease plasmin. (PubMed, ChemMedChem) - "For inhibitor 28 of the second series, the co-crystal structure in complex with a Ser195Ala microplasmin mutant revealed the P2' residue adopts multiple conformations. Most polar contacts to plasmin and surrounding water molecules are mediated through the P1 tranexamoyl residue, whereas the bound conformation of the macrocycle is mainly stabilized by two intramolecular hydrogen bonds."

Journal

Identification of potential biomarkers for atrial fibrillation and stable coronary artery disease based on WGCNA and machine algorithms. (PubMed, BMC Cardiovasc Disord) - "COL6A3 and FKBP10 may be key biomarkers for AF and CAD, providing new insights into the diagnosis and treatment of this disease."

Biomarker • Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • COL6A3 • FKBP10

Vitreomacular traction: diagnostics, natural course, treatment decision and guideline recommendations (PubMed, Ophthalmologie) - "In addition to pars plana vitrectomy, alternative treatment options, such as intravitreal injection of ocriplasmin and pneumatic vitreolysis are discussed for vitreomacular traction with an associated macular hole; however, ocriplasmin is no longer available in Germany...Pneumatic vitreolysis is controversially discussed due to the increased risk of retinal tears. In one of the current S1 guidelines of the German ophthalmological societies evidence-based recommendations for the diagnostics and treatment of vitreomacular traction are summarized."

Journal • Review • CNS Disorders • Depression • Ophthalmology • Psychiatry • Retinal Disorders

Macular hole: Differential diagnosis, treatment options and new guideline recommendations (PubMed, Ophthalmologie) - "For FTMH associated with vitreomacular traction, alternative treatment options in addition to vitrectomy include intravitreal ocriplasmin injection and pneumatic vitreolysis. The current clinical guidelines of the German ophthalmological societies summarize the evidence-based recommendations for diagnosis and treatment of FTMH."

Journal • Review • Ophthalmology • Retinal Disorders

Scoping review of non-surgical treatment options for macular holes. (PubMed, Surv Ophthalmol) - "Treatments included laser therapy, carbonic anhydrase inhibitors (CAIs), non-steroidal anti-inflammatories (NSAIDs), steroids (topical, subtenons, peribulbar, intravitreal), intravitreal gas, anti-vascular endothelial growth factors (VEGF) and ocriplasmin injections...Although non-surgical MH management approaches show potential for conservative therapy, evidence is limited to support routine use. Stage 1 and traumatic MH may benefit from a short period of observation but the gold standard approach for full-thickness MH remains to be vitrectomy with ILM peel."

Journal • Review • Macular Edema • Ophthalmology • Retinal Disorders

Effect Of Intravitreal Perfluoro Propane (C3f8) In The Management Of Symptomatic Vitreomacular Traction. (PubMed, J Ayub Med Coll Abbottabad) - "Intravitreal C3F8 is a cheaper and safer option for the treatment of vitreomacular traction as compared to pars plana vitrectomy or Ocriplasmin."

Journal

Identification of novel gene signatures and immune cell infiltration in intervertebral disc degeneration using bioinformatics analysis. (PubMed, Front Mol Biosci) - "Drug-gene interaction analysis showed that COL1A1 and COL1A2 were targeted by collagenase clostridium histolyticum, ocriplasmin, and PDGFRA was targeted by 66 drugs or molecular compounds. Our data indicated that the 20 hub genes and immune cell infiltration were involved in the pathological process of IDD. In addition, the PDGFRA and two potential drugs were found to be significant in IDD development."

Gene Signature • Immune cell • Journal • Back Pain • Fibrosis • Musculoskeletal Pain • Oncology • Pain • COL1A1 • COL1A2 • PDGFRA

Macular hole Delphi consensus statement (MHOST). (PubMed, Acta Ophthalmol) - "This Delphi study provides valuable information about the consensus/disagreement on different scenarios encountered during FTMH and LMH management as a guide tosurgical decision-making. High rate of disagreement and/or variable approaches still exist for treating such relatively common conditions."

Journal • Cataract • Ophthalmology • Retinal Disorders

"0,3 cc intravitreal C3F8 injection (pneumatic vitreolysis). Another alternative is ocriplasmin injection." (@esatytkn)

PROTEIN ENGINEERING OF STAPHYLOKINASE WITH IMPROVED THROMBOLYSIS (ESOC 2023) - "The immunogenicity of staphylokinase can be lowered 300-fold by three mutations and its clinical effectivity and safety are noninferior to alteplase... The structural model of staphylokinase in complex with microplasmins was used for computational mutagenesis using the web tool AffiLib... We confirmed that it is possible to improve the affinity of staphylokinase to plasmin by computational design in this study. In further research, we will produce additional mutants using AffiLib, adaptively steered molecular dynamics simulations affinity prediction, ribosomal display, and machine learning, to further increase the effectivity of staphylokinase."

Cardiovascular

Pneumatic vitreolysis versus vitrectomy for the treatment of vitreomacular traction syndrome and macular holes: complication analysis and systematic review with meta-analysis of functional outcomes. (PubMed, Int J Retina Vitreous) - "PPV appears to be the most promising option for MH closure and VMT release, with fewer serious complications than EVL  or PV. However, given the limited number of studies comparing these treatments, further research is needed to establish the superiority of PPV over the other options."

Journal • Retrospective data • Review • Retinal Disorders

A novel recombinant human microplasminogen induced complete posterior vitreous detachment without morphological change of retina in juvenile rabbits. (PubMed, Exp Eye Res) - "Complete PVD was found at vitreous posterior pole of 125 μg rhμPlg-treated eyes without morphological change of retina in juvenile rabbits via intraocular injection. Our results demonstrate that rhμPlg has a potential value in the treatment of vitreoretinopathy."

Journal • Preclinical • Retinal Disorders

An application of causal inference in vitreomacular traction - How does the effect of ocriplasmin on functional and patient-reported outcomes occur (ARVO 2023) - P3 | "If the effect occurs by both direct and indirect means, then mediation brings insights into these causal mechanisms by assessing their relative importance. The practical consequences are important: If we understand the mechanism through which a treatment acts, we might be able to develop treatments with the same effect that are cheaper or have fewer side effect."

Clinical • Patient reported outcomes • Ophthalmology • Retinal Disorders

Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis. (PubMed, Comput Biol Med) - "Taken together, the results of the current study indicated that seven hub genes including COL1A2, COL5A1, COL5A2, SERPINH1, MMP9, SPARC, and COL1A1 which were upregulated in CRC could be used as a diagnostic and progression biomarker of CRC. On the other hand, miR-940 which targets SERPINH1 could be used as a potential biomarker of CRC. More ever, Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, Bevacizumab, Ocriplasmin , and Collagenase clostridium histolyticum were introduced as therapeutic agents for CRC which their therapeutic potential should be evaluated experimentally."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • COL1A1 • COL1A2 • COL5A1 • COL5A2 • MMP9 • SERPINH1

Synthesis and structural characterization of new macrocyclic plasmin inhibitors. (PubMed, ChemMedChem) - "For the first time, four crystal structures of these macrocyclic inhibitors could be determined in complex with a Ser195Ala microplasmin mutant...This binding mode is incompatible with other trypsin-like serine proteases containing a sterically demanding 99-hairpin loop. The crystal structures obtained experimentally explain the excellent selectivity of this inhibitor type as previously hypothesized."

Journal

Identification of the Potential Molecular Mechanism of TGFBI Gene in Persistent Atrial Fibrillation. (PubMed, Comput Math Methods Med) - "Pegcetacoplan, ocriplasmin, and carvedilol were the potential target drugs. We used microdataset to identify the potential functions and mechanisms of the TGFBI and its coexpression genes in AF patients. Our findings suggest that CXCL12, C3, FN1, COL1A2, ACTB, VCAM1, and MMP2 may be the hub genes."

Journal • Atrial Fibrillation • Cardiovascular • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • COL1A2 • CXCL12 • MMP2 • TGFBI • VCAM1

Identification of the circRNA-miRNA-mRNA regulatory network in osteoarthritis using bioinformatics analysis. (PubMed, Front Genet) - "Finally, three chemicals (noscapine, diazepam, and TG100-115) based on CMap analysis and two drugs (collagenase Clostridium histolyticum and ocriplasmin) based on DGIdb were discovered as potential treatment options for OA. This study presents novel perspectives on the pathogenesis and treatment of OA based on circRNA-related competitive endogenous RNA regulatory networks."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • COL1A1 • COL5A1 • COL6A3 • MIR1207 • SERPINH1

Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model. (PubMed, PLoS One) - "The developed multivariable model using 'horizontal VMT diameter' and 'age' is a valid tool for prediction of VMT resolution upon IVO treatment."

Journal • Retinal Disorders